Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447671 | 0.98 | KDM4E (0.66) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL2142228 | 0.98 | KDM4E (0.66) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL157010 | 0.98 | KDM4E (0.66) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL30287648 | 0.97 | KDM4E (0.63) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| Bicarbonate SCHEMBL23462324 | 0.93 | KDM4E (0.59) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| Hexamethonium SCHEMBL8821557 | 0.84 | KDM4E (0.49) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL18577849 | 0.82 | KDM4E (0.46) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL29710685 | 0.81 | KDM4E (0.61) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| Potassium Ion SCHEMBL30898940 | 0.81 | KDM4E (0.61) | KDM4ESMN1; SMN2HTTANPEPERAP2 | |
| SCHEMBL13359411 | 0.81 | KDM4E (0.43) | KDM4ESMN1; SMN2HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114752035-A | High-solid-content aqueous polyurethane dispersion and preparation method and application thereof | 浙江大学衢州研究院 | 2022-07-15 | — | — | CN | claimed |
| EP-4347928-A1 | ELECTROCHEMICAL METAL DEPOSITION SYSTEM AND METHOD | NTH Cycle, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-4230042-A1 | ANTIPATHOGENIC DRUG, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN PROCESSING DEVICE, METHOD FOR PRODUCING ANTIPATHOGENIC DRUG, ANTIBACTERIAL METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN PROCESSING METHOD | Acenet Inc. (JP) | 2023-08-23 | — | — | EP | disclosed |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-4147703-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115666593-A | Therapeutic agent for epithelial cancer | 国立大学法人大阪大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20220389601-A1 | ELECTROCHEMICAL METAL DEPOSITION SYSTEM AND METHOD | Nth Cycle, Inc. (US) | 2022-12-08 | — | — | US | disclosed |
| US-11041097-B2 | Polishing composition and method of fabricating semiconductor device using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-06-22 | — | — | US | disclosed |
| WO-2021066080-A1 | DRUG, DRUG MANUFACTURING METHOD, AND WATER PURIFICATION METHOD | 株式会社エースネット | 2021-04-08 | — | — | WO | disclosed |
| US-20200255689-A1 | POLISHING COMPOSITION AND METHOD OF FABRICATING SEMICONDUCTOR DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-08-13 | — | — | US | disclosed |
| US-20200171118-A1 | RADICAL GENERATING CATALYST, METHOD FOR PRODUCING RADICAL, METHOD FOR PRODUCING OXIDATION REACTION PRODUCT, DRUG, AND DRUG FOR USE IN AGRICULTURE AND LIVESTOCK INDUSTRY | ACENET INC. (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3626339-A1 | RADICAL-GENERATING CATALYST, RADICAL PRODUCTION METHOD, OXIDATION REACTION PRODUCT PRODUCTION METHOD, CHEMICAL AGENT, AND CHEMICAL AGENT FOR AGRICULTURE AND LIVESTOCK | Acenet Inc. (JP) | 2020-03-25 | — | — | EP | disclosed |
| EP-2475778-B1 | Methods and kit for protease enzyme assays | 3M INNOVATIVE PROPERTIES CO (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8349580-B2 | Methods and kit for protease enzyme assays | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2475778-A1 | METHODS AND KIT FOR PROTEASE ENZYME ASSAYS | 3M Innovative Properties Company (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120164675-A1 | METHODS AND KIT FOR PROTEASE ENZYME ASSAYS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-06-28 | — | — | US | disclosed |
| WO-2011031573-A1 | METHODS AND KIT FOR PROTEASE ENZYME ASSAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | KDM4E 1296/4885SMN1; SMN2 3710/4885HTT 2471/4885 |
| US-20200171118-A1 | RADICAL GENERATING CATALYST, METHOD FOR PRODUCING RADICAL, METHOD FOR PRODUCING OXIDATION REACTION PRODUCT, DRUG, AND DRUG FOR USE IN AGRICULTURE AND LIVESTOCK INDUSTRY | PRDX2, PRDX1, PRDX5 | KDM4E 1991/4885SMN1; SMN2 4603/4885HTT 3756/4885 |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | EPCAM, EGFR, MUC1 | KDM4E 3793/4885SMN1; SMN2 4559/4885HTT 4651/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | KDM4E 4109/4885SMN1; SMN2 3556/4885HTT 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.